Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy-Reference-Cited by-同舟云学术

Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy

Published:1996-02 Issue:8997 Volume:347 Page:297-299
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Jensen B.V,Skovsgaard T,Nielsen S.L

Publisher

Elsevier BV

Subject

General Medicine

Reference12 articles.

1. Risk factors for doxorubicin-induced congestive heart failure;Von Hoff;Ann Intern Med,1979

2. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection;Mortensen;Int J Clin Pharmacol Res,1986

3. Adriamycin cardiotoxicity: a survey of 1273 patients;Praga;Cancer Treat Rep,1979

4. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer;Nielsen;J Clin Oncol,1990

5. A clinicopathologic analysis of adriamycin cardiotoxicity;Lefrak;Cancer,1973

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress on the role and mechanism of Sirtuin family in doxorubicin cardiotoxicity;Phytomedicine;2024-07

2. Evaluation of Ameliorative Effect of Quercetin and Candesartan in Doxorubicin-Induced Cardiotoxicity;Vascular Health and Risk Management;2022-12

3. Role of angiotensin-converting enzyme inhibitors on changes in troponin levels in breast cancer with anthracycline chemotherapy;Bali Medical Journal;2021-08-11

4. How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice;Kardiologia Polska;2021-02-25

5. Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies;Oxidative Medicine and Cellular Longevity;2021-01-25